HR9559Referred to Committee

To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-06-30
Introduced
3
Cosponsors
HR
Type

Sponsor

Morgan Luttrell
Morgan Luttrell
Republican · TX · Representative
Votes with party: 95.8% (577 recorded votes)

Full profile: /officials/L000603

Source: Congress.gov · FEC

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2026-06-30

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

The proposal would speed up the research, development, and approval process for psychedelic drugs—such as psilocybin and MDMA—that researchers believe could treat serious mental health conditions like depression, PTSD, and anxiety. It aims to make these experimental treatments available to patients faster while potentially helping address the mental health crisis affecting millions of Americans. The bill has been sent to three House committees for review.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Full bill text is not yet cached locally.